FFA
CRSP icon

Farther Finance Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Farther Finance Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$632K Buy
11,426
+3,470
+44% +$187K ﹤0.01% 1415
2026
Q2 		$434K Sell
7,956
-995
-11% -$52.4K ﹤0.01% 1655
2026
Q1 		$437K Buy
8,951
+211
+2% +$11.1K ﹤0.01% 1499
2025
Q4 		$458K Buy
8,740
+1,235
+16% +$74K ﹤0.01% 1364
2025
Q3 		$486K Sell
7,505
-588
-7% -$33.8K 0.01% 1081
2025
Q2 		$394K Buy
8,093
+2,467
+44% +$95.5K 0.01% 1029
2025
Q1 		$186K Buy
5,626
+1,792
+47% +$76K ﹤0.01% 1257
2024
Q4 		$151K Buy
3,834
+977
+34% +$46.1K 0.01% 1123
2024
Q3 		$134K Buy
2,857
+195
+7% +$9.89K 0.01% 1174
2024
Q2 		$144K Buy
2,662
+68
+3% +$3.93K 0.01% 983
2024
Q1 		$177K Buy
2,594
+502
+24% +$35.9K 0.01% 728
2023
Q4 		$131K Buy
2,092
+1,892
+946% +$105K 0.01% 702
2023
Q3 		$9.08K Sell
200
-160
-44% -$8.26K ﹤0.01% 1318
2023
Q2 		$20.2K Sell
360
-379
-51% -$21.5K ﹤0.01% 993
2023
Q1 		$33.4K Buy
739
+728
+6,618% +$35.4K 0.01% 732
2022
Q4 		$447 Buy
+11
New +$584 ﹤0.01% 1854

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $166M AUM 19.36% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Farther Finance Advisors's CRSP Position: Q3 2026 in Review

Farther Finance Advisors increased its CRISPR Therapeutics (CRSP) stake by 44% in Q3 2026, buying an estimated $187K and bringing the position to 11,426 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

Farther Finance Advisors first reported a position in CRSP in Q4 2022 and has held it in 16 quarters since. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Farther Finance Advisors held 11,426 shares of CRISPR Therapeutics worth $632K as of Q3 2026.
  • Farther Finance Advisors bought 3,470 CRISPR Therapeutics shares in Q3 2026, an estimated $187K.
  • CRISPR Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1415 holding.
  • Farther Finance Advisors first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.